UBS Group upgraded shares of Roche Holdings AG Basel (OTCMKTS:RHHBY) from a neutral rating to a buy rating in a report published on Friday, The Fly reports.

Other research analysts have also recently issued reports about the stock. Liberum Capital restated a buy rating and set a GBX 525 ($6.86) price target on shares of in a report on Thursday, June 20th. Zacks Investment Research upgraded shares of DLH from a sell rating to a hold rating in a research note on Tuesday, July 9th. Finally, Deutsche Bank reiterated a buy rating and issued a GBX 2,450 ($32.01) target price on shares of in a research note on Thursday, June 20th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $37.00.

Roche Holdings AG Basel stock traded up $0.59 during midday trading on Friday, hitting $33.86. 1,166,388 shares of the stock were exchanged, compared to its average volume of 1,081,196. Roche Holdings AG Basel has a 52-week low of $28.74 and a 52-week high of $35.90. The company has a market capitalization of $231.38 billion, a PE ratio of 14.59, a price-to-earnings-growth ratio of 2.42 and a beta of 0.49. The stock’s 50-day simple moving average is $34.56.

Hedge funds have recently made changes to their positions in the stock. Advisors Asset Management Inc. purchased a new stake in shares of Roche Holdings AG Basel during the 1st quarter valued at approximately $144,000. Beck Mack & Oliver LLC purchased a new stake in shares of Roche Holdings AG Basel during the 1st quarter valued at approximately $203,000. South Texas Money Management Ltd. purchased a new stake in shares of Roche Holdings AG Basel during the 1st quarter valued at approximately $215,000. MAI Capital Management purchased a new stake in shares of Roche Holdings AG Basel during the 1st quarter valued at approximately $220,000. Finally, Dearborn Partners LLC lifted its stake in shares of Roche Holdings AG Basel by 11.9% during the 1st quarter. Dearborn Partners LLC now owns 9,339 shares of the company’s stock valued at $321,000 after buying an additional 992 shares in the last quarter. Institutional investors own 0.30% of the company’s stock.

Roche Holdings AG Basel Company Profile

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.

Featured Article: What is a stock portfolio tracker?

The Fly

Analyst Recommendations for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.